LIVN
LivaNova Plc
NASDAQ · Healthcare · Medical - Devices · GB
$78.14
+0.72%Year over year
Reported trailing growth
- Revenue
- +12.4%
- EBITDA
- +424.3%
- EBIT
- +13.0%
- EPS
- +189.1%
- Free cash flow
- -8.5%
- Operating cash flow
- +15.1%
Forward estimates
Based on analyst estimates
- Revenue
- +8.6%
- EBITDA
- +112.5%
- EPS
- +31.3%
Three-year CAGR
- Revenue
- +10.8%
- EBITDA
- —
- EBIT
- +54.5%
- Net income
- —
- EPS
- —
- Free cash flow
- +58.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026